Moderna (MRNA) Return on Sales (2017 - 2026)

Moderna (MRNA) has 10 years of Return on Sales data on file, last reported at 0.03% in Q1 2026.

• On a quarterly basis, Return on Sales rose 6.0% year-over-year to 0.03% in Q1 2026; TTM through Mar 2026 was 0.01%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.03%, down from 0.01% in the prior quarter.
• Over the last five years, Return on Sales for MRNA reached as high as 0.01% in Q1 2022 and fell as low as 0.09% in Q1 2025.
• Historically, Return on Sales has averaged 0.02% across 5 years, with a median of 0.01% in 2024.
• Across the five-year window, Return on Sales dropped 7 bps in 2024 and climbed 6 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then slumped by 73 bps to 0.0% in 2023, then slumped by 1602 bps to 0.01% in 2024, then retreated by 5 bps to 0.01% in 2025, then slumped by 183 bps to 0.03% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.03% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.